Similar Suvival, Tolerability For Adjuvant Chemotherapy, Radiotherapy in Gastric Cancer
the Cancer Therapy Advisor take:
A recently conducted trial entitled The Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) sought to determine if the inclusion of radiotherapy with adjuvant chemotherapy improved the rate of disease-free survival in patients with D2-resected gastric cancer.
The research was conducted between November 2004 and April 2008 and 458 patients with gastric cancer who had a D2 lymph node dissection were randomly assigned to received either six cycle of adjuvant chemotherapy with capecitabine and cisplatin or to two cycle of capecitabine and cisplatin followed by chemoradiotherapy and then two cycle of capecitabine and cisplatin.
The researchers found that after 7 years of follow-up, disease-free survival rates remained similar between the two groups (hazard ratio [HR], 0.740; 95% CI, 0.520,1.050; P=0.0922).
Overall survival was also determined to be similar between the treatment groups (HR, 1.130; 95% CI, 0.775,1.647; P=0.5272). Subgroup analyses were conducted and they indicated that chemoradiotherapy was shown to significantly improve disease free survival in patients with node-positive disease and with intestinal-type GC.
The researchers conclude that in patients with D2-resected gastric cancer adjuvant chemotherapy and chemoradiotherapy are equally tolerated and able to prevent the relapse of disease. Due to the findings in regard to certain subsets of patients, additional research is underway in patients with node-positive D2-resected gastric cancer.
Inclusion of radiotherapy with adjuvant chemotherapy improved the rate of survival in D2-resected gastric cancer.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma
- Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC
- Affordable Care Act Linked to Lower Rates of Cancer Diagnosis Among Uninsured
- FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma, Questions Remain About Cost and Toxicity
- PAK Inhibition Could Abrogate MAPK Inhibitor Resistance in BRAF-mutant Melanoma
- Lung Cancer Treatment in North America: Recent Advances and Future Promises
- Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC